Super Micro Computer surged 16.6% on the week to $41.54 — and the short base that rebuilt so aggressively through mid-September is now quietly unwinding again.
The positioning story is the most interesting tension here. Last week's note documented a sharp short rebuild — from 80.2 million shares to 96.1 million by September 15 — as bears re-engaged during a price slide. That conviction has already started to crack. Short interest edged down 0.7% on the week to 95.3 million shares, still representing a heavy 16.0% of the free float, but the directional change matters: shorts rebuilt into weakness and are now trimming into strength. The ORTEX short score has eased slightly from 61.9 on September 15 to 60.3 by September 22, a modest but consistent drift lower as the price recovery takes hold. Borrow conditions remain relaxed — cost to borrow is just 0.47%, essentially unchanged — and availability has actually loosened to 245%, up 22% on the week, meaning the lending pool has more capacity now than it did at the start of the move. There is no squeeze pressure forcing covers; the trimming looks discretionary.
Options traders are less relaxed. The put/call ratio of 0.76 is running about 1.7 standard deviations above its 20-day average of 0.73 — not extreme, but elevated enough to suggest the rally has brought more hedging demand with it rather than pure bullish conviction. The PCR has climbed steadily since late August, when it sat near 0.69. That trajectory, combined with the still-elevated short base, creates a setup where the stock is going up but institutional risk-management is getting incrementally more defensive around it.
The Street is broadly cautious but nudging higher. After the August earnings beat — the stock jumped nearly 20% on the day and held most of that gain over five sessions — analysts lifted targets across the board. The moves were incremental rather than transformative: Citigroup raised to $39 (Neutral), Barclays to $39 (Equal-Weight), Wedbush to $40 (Neutral), Mizuho to $35 (Neutral). Goldman Sachs raised its Sell-rated target to $34. Only Needham at $46 and Rosenblatt at $51 carry unambiguously positive conviction. The mean target of $42.37 sits almost exactly at the current price — the stock has effectively rallied into consensus. These analyst actions date from August 12, now six weeks old; given the subsequent 16% weekly move, some of those targets may already be stale. The factor picture adds nuance: EPS surprise ranks in the 89th percentile and 90-day EPS momentum is at the 96th percentile, reflecting a genuine earnings revision cycle. But the short score rank in the 7th percentile means the stock screens as one of the more heavily shorted names in the universe, and the forward earnings yield multiple (PE near 8.2x) has expanded about 1.1 turns over the past 30 days as the price has recovered.
The ownership register adds one notable detail. CEO Charles Liang and director Sara Liu Liang each sold 100,000 shares on September 4 at $40.00 per share — $4 million apiece — under pre-arranged 10b5-1 plans. Planned sales carry far less signal than discretionary ones, and these appear to be part of an ongoing programme. But the price level is worth noting: those sales happened almost exactly at current prices, which means the stock has now returned to the same level where founders chose to trim. BlackRock added 4.3 million shares through August, and Vanguard-affiliated entities collectively hold north of 11% in two separate vehicles. Jane Street trimmed its position from 8.5% to 7.4% of the class as of mid-August, a modest reduction but worth watching given its size.
The next earnings event is scheduled for November 3. The prior two prints produced one-day moves of +20% and +6%, both to the upside — a pattern that keeps the bull case alive but also explains why a 16% float sits short heading into the report. With the stock back at analyst consensus and inside selling at these exact levels, the week ahead turns on whether the short base continues its cautious retreat or reasserts the conviction that drove the September rebuild.
See the live data behind this article on ORTEX.
Open SMCI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
